AlphaStocks
5.1
Consider Buy

Astrana Health, Inc. (ASTH)

Health Care / Health Care Facilities

S&P SmallCap 600

$38.97

Below average on several measures. Research carefully.

Consider Buy

Score based on 5 of 5 models — high confidence

#534out of 1125 in Health Care

Is Astrana Health, Inc. a Good Investment in 2026?

Astrana Health, Inc. (ASTH) scores 5.1 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Greenblatt Magic Formula model rates Astrana Health, Inc. as Attractive (Top 25% (rank 21%)). However, the Lynch model rates it Caution — High PEG — growth premium · Slow Grower. Astrana Health, Inc. currently trades above its estimated fair value of $28, suggesting limited upside at current prices. Astrana Health, Inc. ranks #534 out of 1125 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E71.0ROE3.5Market Cap2B

Estimated Fair Value

$27.5841% above

Trading above estimated fair value. P/e of 71x implies high growth expectations. eps growth of -47% may not justify the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

3/9

Buffett

Caution

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Caution

High PEG — growth premium · Slow Grower

Greenblatt

Attractive

Top 25% (rank 21%)

Frequently Asked Questions

Is Astrana Health, Inc. (ASTH) a good investment?
Based on AlphaStocks' composite analysis, Astrana Health, Inc. (ASTH) scores 5.1 out of 10, earning a Consider Buy rating. This score is below average, suggesting caution. Trading above estimated fair value. P/e of 71x implies high growth expectations. eps growth of -47% may not justify the premium.
What is Astrana Health, Inc.'s Piotroski F-Score?
Astrana Health, Inc.'s Piotroski F-Score status is Neutral. The raw score is 3/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is ASTH overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $28, ASTH appears overvalued. The stock currently trades 41% above its estimated fair value. Trading above estimated fair value. P/e of 71x implies high growth expectations. eps growth of -47% may not justify the premium.
How does ASTH compare to other Health Care stocks?
Astrana Health, Inc. ranks #534 out of 1125 stocks in the Health Care sector, placing it in the top 47% of its sector by composite score. This is an above-average position relative to sector peers.
What do investment models say about ASTH?
AlphaStocks evaluates ASTH using five proven investment models. Piotroski: Neutral; Buffett: Caution; Graham: Caution; Lynch: Caution; Greenblatt Magic Formula: Attractive. These models are combined into a single composite score of 5.1/10.

Similar Stocks

BFAMAZNKLIC

Compare ASTH with

ASTH vs BFAMASTH vs AZNASTH vs KLIC

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer